Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Seizures × Temozolomide × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 403 Brain Neoplasms 162 Glioma 158 Gliosarcoma 126 Astrocytoma 115 Central Nervous System Neoplasms 109 Oligodendroglioma 74 Neuroblastoma 44 Medulloblastoma 33 Ependymoma 26 Recurrence 23 Neoplasms 19 Neoplasm Metastasis 16 Diffuse Intrinsic Pontine Glioma 15 Choroid Plexus Neoplasms 13 Optic Nerve Glioma 11 Melanoma 11 Spinal Cord Neoplasms 10 Rhabdoid Tumor 10 Lymphoma 9 Familial ependymoma 9 Rhabdomyosarcoma 8 Osteosarcoma 8 Neuroectodermal Tumors, Primitive 8 Breast Neoplasms 8 Sarcoma, Ewing 6 Sarcoma 6 Pinealoma 6 Neuroectodermal Tumors, Primitive, Peripheral 6 Glioma, Subependymal 6

Interventions

Levetiracetam 6 perampanel 2 Tranexamic Acid 2 Standard of Care 2 ziprasidone 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Tobramycin 1 Temozolomide 1 Spironolactone 1 Sodium Chloride 1 Sevelamer 1 Saline Solution 1 Rocuronium 1 Pregabalin 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1 Nifedipine 1 Nafcillin 1 Molindone 1 Methylprednisolone 1 Mental Status and Dementia Tests 1 Magnetic Resonance Spectroscopy 1 Magnesium Sulfate 1 Lurasidone Hydrochloride 1 Labetalol 1 Haloperidol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04450160 2020-06-29

AEO

MetVital, Inc.

Phase 2 Unknown

Glioblastoma, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡